Skip to main content

Cytomegalovirus Retinitis

9
Pipeline Programs
7
Companies
16
Clinical Trials
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
3
0
3
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1785%
Monoclonal Antibody
315%
+ 10 programs with unclassified modality

On Market (1)

Approved therapies currently available

Roche
CYTOVENEApproved
ganciclovir
Roche
oral1994

Competitive Landscape

7 companies ranked by most advanced pipeline stage

Roche
RocheSTAVANGER NORWAY, Norway
2 programs
1
GanciclovirN/ASmall Molecule1 trial
ZidovudineN/A4 trials
Active Trials
NCT00002135Completed
NCT00000976Completed40
NCT00002034Completed100
+2 more trials
Genentech
GenentechCA - Oceanside
13 programs
2
1
3
GanciclovirPhase 3Small Molecule
ValganciclovirPhase 3Small Molecule
ValganciclovirPhase 3Small Molecule
GanciclovirPhase 2Small Molecule
Foscarnet sodiumPhase 1
+8 more programs
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
5 programs
1
SevirumabPhase 2Monoclonal Antibody1 trial
CidofovirN/ASmall Molecule
Foscarnet sodiumN/A4 trials
GanciclovirPHASE_1Small Molecule1 trial
GanciclovirPHASE_1Small Molecule
Active Trials
NCT00000726Completed53Est. Feb 1992
NCT00000729Completed10Est. Jun 1992
NCT00000665Completed240
+3 more trials
Kite Pharma
Kite PharmaCA - El Segundo
4 programs
1
CidofovirPhase 2Small Molecule
CidofovirN/ASmall Molecule
CidofovirN/ASmall Molecule
CidofovirN/ASmall Molecule
Ionis Pharmaceuticals
4 programs
Fomivirsen sodiumN/A1 trial
Fomivirsen sodiumN/A1 trial
Fomivirsen sodiumPHASE_21 trial
Fomivirsen sodiumPHASE_21 trial
Active Trials
NCT00002187Completed
NCT00002355Completed60
NCT00002356Completed
+1 more trials
Sandoz
SandozAustria - Kundl
1 program
SevirumabPHASE_1Monoclonal Antibody1 trial
Active Trials
NCT00002016Completed
Novartis
NovartisBASEL, Switzerland
1 program
SevirumabPHASE_1Monoclonal Antibody

Clinical Trials (16)

Total enrollment: 1,292 patients across 16 trials

A Phase II/III Trial of Human Anti-CMV Monoclonal Antibody MSL 109 (MACRT)

Est. completion: Aug 1998300 patients
Phase 2Completed

A Randomized Comparison of Intravitreal ISIS 2922 Plus Ganciclovir Versus Ganciclovir as Treatment for Patients With Cytomegalovirus Retinitis ( CMVR )

194 patients
Phase 2Completed

The Safety and Effectiveness of ISIS 2922 in Patients With AIDS Who Have Cytomegalovirus (CMV) of the Eyes

Phase 2Completed

A Study of Ganciclovir in the Treatment of Cytomegalovirus of the Eyes

Est. completion: Jan 199825 patients
Phase 1Completed

Foscarnet Treatment of Serious CMV Retinitis Infection in Patients With Acquired Immunodeficiency Syndrome

Est. completion: Feb 199253 patients
Phase 1Completed

A Multicenter Study To Determine Foscarnet Dose Response in HIV Infected Patients With PGL and/or Constitutional Disease

Est. completion: Jun 199210 patients
Phase 1Completed

The Effect of Stomach Acid on Foscarnet

Est. completion: Oct 19906 patients
Phase 1Completed

A Phase I Study of the Safety and Pharmacokinetics of Recombinant Human CD4-Immunoglobulin G (rCD4-IgG) Administered by Intravenous Bolus Injection in Combination With Oral Zidovudine in Patients With AIDS and AIDS-Related Complex

40 patients
Phase 1Completed

A Randomized Study of Activity, Safety, and Tolerance of Oral Ro 24-7429 (Tat Antagonist) in Patients With HIV Infection

96 patients
Phase 1Completed

A Phase I/II Trial of Vaccine Therapy of HIV-1 Infected Individuals With 50-500 CD4 Cells/mm3

Est. completion: Mar 1993168 patients
Phase 1Completed

A Phase I/II Trial to Assess the Safety and Tolerance of Escalating Doses of a Human Anti-Cytomegalovirus Monoclonal Antibody (SDZ MSL-109) in Patients With the Acquired Immunodeficiency Syndrome and CMV Retinitis

Phase 1Completed

A Comparison of ISIS 2922 Used Immediately or Later in Patients With Cytomegalovirus (CMV) of the Eyes

60 patients
N/ACompleted

A Study of ISIS 2922 in the Treatment of Advanced Cytomegalovirus Retinitis

N/ACompleted
NCT00002135RocheGanciclovir

An Open-Label Safety Study of Oral Ganciclovir Maintenance Treatment of CMV Retinitis in People With Limited Venous Access

N/ACompleted

Studies of the Ocular Complications of AIDS (SOCA) CMV Retinitis Trial: Foscarnet-Ganciclovir Component

240 patients
N/ACompleted

A Study of the Safety and Tolerance of Long-Term Therapy With Intravenous Cytovene (Ganciclovir Sodium) for Cytomegalovirus Retinitis in Persons With AIDS

100 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 late-stage (Phase 3) programs, potential near-term approvals
Small Molecule is the dominant modality (85% of programs)
7 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.